Elimination of cis -cleavage in CRISPR diagnostics for one-pot rapid nucleic acid detection
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkag267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Wenhao Yin und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Hubei 430042, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Nucleic Acid Amplification Techniques, Clustered Regularly Interspaced Short Palindromic Repeats. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Science and Technology Innovation Talent Plan of Hubei Province, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Current one-pot clustered regularly interspaced short palindromic repeats diagnostics are limited by the cis-cleavage activity of Cas nucleases, which leads to amplicon degradation during amplification. Here, we report a streamlined strategy that overcomes this limitation. By integrating a bipartite split-crRNA into Cas12a (SCas12a), we separate target recognition from PAM dependency and completely eliminate cis-cleavage while preserving robust trans-cleavage. This strategy is broadly applicable for one-pot testing, compatible with recombinase polymerase amplification, RT–RPA, and loop-mediated isothermal amplification, as well as multiple Cas12a orthologs, including As, Lb, and Ct Cas12a. Moreover, the SCas12a accelerates one-pot testing with 100–1000-fold improved sensitivity and achieves >10-fold reduction in time-to-signal, enabling detection of targets at attomolar levels within 30 min. Additionally, it provides single-base resolution with up to 91-fold selectivity. The system has been successfully applied to detect HPV16, SARS-CoV-2, and TP53 SNPs in clinical samples. Together, we have developed a PAM-independent and cis-cleavage-free one-pot Cas12a assay, which holds strong potential for point-of-care diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Hubei 430042, China.
- School of Life Science and Technology, Wuhan Polytechnic University, Hubei 430023, China.
- Department of Cardiology, Zhongnan Hospital of Wuhan University, Hubei 430071, China.
- Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450001, China.
- BravoVax Co., Ltd., Wuhan, Hubei 430075, China.
ORCID-Profile: Yi Liu
Förderung
- National Key Research and Development Program of China
- Science and Technology Innovation Talent Plan of Hubei Province
- Natural Science Foundation of Hubei Province
Zitieren
APA
Yin, W., Jin, Z., Jiang, Q., Jin, S., Wang, X., He, R., Qiao, B., Qiao, J., Zhang, X., & Liu, Y. (2026). Elimination of cis -cleavage in CRISPR diagnostics for one-pot rapid nucleic acid detection. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag267
Vancouver
Yin W, Jin Z, Jiang Q, Jin S, Wang X, He R, et al. Elimination of cis -cleavage in CRISPR diagnostics for one-pot rapid nucleic acid detection. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag267
BibTeX
@article{Yin2026,
author = {Yin, Wenhao and Jin, Zhili and Jiang, Qingyuan and Jin, Shuqi and Wang, Xinping and He, Ruyi and Qiao, Bin and Qiao, Jie and Zhang, Xianhua and Liu, Yi},
title = {Elimination of cis -cleavage in CRISPR diagnostics for one-pot rapid nucleic acid detection},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkag267}
}
EUVIMED